PT - JOURNAL ARTICLE AU - Dan, Jennifer M. AU - Mateus, Jose AU - Kato, Yu AU - Hastie, Kathryn M. AU - Faliti, Caterina E. AU - Ramirez, Sydney I. AU - Frazier, April AU - Yu, Esther Dawen AU - Grifoni, Alba AU - Rawlings, Stephen A. AU - Peters, Bjoern AU - Krammer, Florian AU - Simon, Viviana AU - Saphire, Erica Ollmann AU - Smith, Davey M. AU - Weiskopf, Daniela AU - Sette, Alessandro AU - Crotty, Shane TI - Immunological memory to SARS-CoV-2 assessed for greater than six months after infection AID - 10.1101/2020.11.15.383323 DP - 2020 Jan 01 TA - bioRxiv PG - 2020.11.15.383323 4099 - http://biorxiv.org/content/early/2020/11/16/2020.11.15.383323.short 4100 - http://biorxiv.org/content/early/2020/11/16/2020.11.15.383323.full AB - Understanding immune memory to SARS-CoV-2 is critical for improving diagnostics and vaccines, and for assessing the likely future course of the pandemic. We analyzed multiple compartments of circulating immune memory to SARS-CoV-2 in 185 COVID-19 cases, including 41 cases at ≥6 months post-infection. Spike IgG was relatively stable over 6+ months. Spike-specific memory B cells were more abundant at 6 months than at 1 month. SARS-CoV-2-specific CD4+ T cells and CD8+ T cells declined with a half-life of 3-5 months. By studying antibody, memory B cell, CD4+ T cell, and CD8+ T cell memory to SARS-CoV-2 in an integrated manner, we observed that each component of SARS-CoV-2 immune memory exhibited distinct kinetics.Competing Interest StatementA.S. is a consultant for Gritstone, Flow Pharma, Merck, Epitogenesis, Gilead and Avalia. S.C. is a consultant for Avalia. LJI has filed for patent protection for various aspects of T cell epitope and vaccine design work. Mount Sinai has licensed serological assays to commercial entities and has filed for patent protection for serological assays. D.S., F.A., V.S. and F.K. are listed as inventors on the pending patent application (F.K., V.S.), and Newcastle disease virus (NDV)-based SARS-CoV-2 vaccines that name F.K. as inventor. All other authors declare no conflict of interest.